U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487363) titled 'TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD' on March 14.
Brief Summary: This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers
Study Start Date: Feb. 05
Study Type: INTERVENTIONAL
Condition:
Atherosclerotic Cardiovascular Diseases
Endothelial Dysfunction
Intervention:
DRUG: TB-500
(thymosin b...